SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David Culver who wrote (1184)2/10/1999 10:15:00 PM
From: Harold Lehman  Read Replies (1) of 1501
 
I also asked Jeff Bacha about the tb antigen test as well. As you know it's licensed to Cortecs Pharmaceuticals, which had management changes at the highest levels late last year. Inflazyme has been in frequent contact with them to ascertain whether the continued development of this test is still a high-priority item with them. When I asked whether this test, which has had a lot of developmental work by Cortecs, could revert back to Inflazyme, I was told that they hope to get an answer soon from Cortecs, and then they'll see. I had the distinct impression that it could revert back to IZP if it's not high priority with Cortecs. That, in my opinion, would be good, as a lot of work has been put into it already, and I believe it has a very large, if not huge, market.

Harold
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News